- Home
- GROY vs KROS Comparison
GROY vs KROS Comparison
Compare GROY & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GROY | KROS |
|---|---|---|
| Founded | 2020 | 2015 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 618.0M | 565.0M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | GROY | KROS |
|---|---|---|
| Price | $4.09 | $21.54 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 15 |
| Target Price | $5.00 | ★ $22.20 |
| AVG Volume (30 Days) | ★ 3.6M | 1.1M |
| Earning Date | 11-05-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.57 |
| Revenue | $14,464,000.00 | ★ $246,718,000.00 |
| Revenue This Year | $71.94 | $6,876.34 |
| Revenue Next Year | $66.48 | N/A |
| P/E Ratio | ★ N/A | $13.66 |
| Revenue Growth | 86.30 | ★ 37798.31 |
| 52 Week Low | $1.16 | $9.12 |
| 52 Week High | $4.49 | $22.55 |
Technical Indicators
Market Signals| Indicator | GROY | KROS |
|---|---|---|
| Relative Strength Index (RSI) | 54.72 | 75.04 |
| Support Level | $3.96 | $20.78 |
| Resistance Level | $4.49 | $22.20 |
| Average True Range (ATR) | 0.25 | 0.97 |
| MACD | -0.01 | 0.35 |
| Stochastic Oscillator | 59.09 | 83.47 |
Price Performance
Historical ComparisonAbout GROY Gold Royalty Corp.
Gold Royalty Corp is a precious metals-focused royalty and mineral streaming company. The company offers creative financing solutions to the metals and mining industry. The company's mission is to acquire royalties, streams and similar interests at varying stages of the mine life cycle to build a balanced portfolio offering near, medium and longer-term attractive returns for investors. It has its business as a single operating segment, being the investment in royalty and mineral stream interests. The company derives maximum revenue from Canada.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.